In this study, we pinpointed fostamatinib, an orally delivered small molecule SYK inhibitor for chronic immune thrombocytopenia (ITP), as a promising candidate for drug repurposing. This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.